Lilly and AC Immune Announce License and Collaboration Agreement

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF6... Biopharmaceuticals, Neurology, Licensing Eli Lilly, AC Immune, Morphomer tau aggregation, Alzheimer's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news